Search Results
3-TYP 50 mg | 100.00%
TargetMol
3-TYP 25 mg | 100.00%
TargetMol
3-TYP 10 mg | 100.00%
TargetMol
BPTU 100 mg | 99.89%
TargetMol
Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation.
More Information Supplier PageBPTU 10 mg | 99.89%
TargetMol
Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation.
More Information Supplier PageCY-09 5 mg | Purity Not Available
TargetMol
CY-09 10 mg | Purity Not Available
TargetMol
PCC0208009 5 mg | 99.89%
TargetMol
PCC0208009 (IDO-IN-2) is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1.
More Information Supplier PagePCC0208009 25 mg | 99.89%
TargetMol
PCC0208009 (IDO-IN-2) is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1.
More Information Supplier Page
